• EZ Cap™ Cas9 mRNA (m1Ψ): Precision Genome Editing with Cap1

  2026-05-07

  EZ Cap™ Cas9 mRNA (m1Ψ) empowers researchers with enhanced genome editing efficiency, low immunogenicity, and robust mRNA stability, thanks to its Cap1 structure and m1Ψ modifications. Discover how this APExBIO innovation overcomes typical delivery and specificity challenges in mammalian CRISPR workflows, setting a new benchmark for reliable, high-precision editing.

• Red Blood Cell Lysis Buffer: Precision in Erythrocyte Remova

  2026-05-07

  Unlock unparalleled accuracy in blood sample preparation with Red Blood Cell Lysis Buffer. This optimized erythrocyte lysis buffer streamlines workflows for flow cytometry, nucleic acid, and protein extraction—delivering robust lymphocyte recovery and reproducibility that stands out in translational research.

• Cefiderocol vs β-Lactam Inhibitors Against MDR Non-Fermenter

  2026-05-06

  This large-scale European study systematically compared the in vitro efficacy of cefiderocol with β-lactam/β-lactamase inhibitor combinations against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. isolates. The findings establish cefiderocol's superior activity, especially against carbapenem-resistant strains, and provide guidance for susceptibility testing in antimicrobial research.

• NLRP3 Knockdown Modulates Pyroptosis and Ferroptosis in DCM

  2026-05-06

  Wang et al. (2024) delineate how NLRP3 inflammasome knockdown mitigates diabetic cardiomyopathy (DCM) by suppressing both pyroptosis and ferroptosis in cardiac tissue. The study demonstrates that mitochondrial ROS, specifically induced using rotenone, reverses this protection—highlighting an interdependent regulatory axis between NLRP3 and mitochondrial oxidative stress.

• Lamotrigine: Mechanistic Evidence for CNS and Cardiac Resear

  2026-05-05

  Lamotrigine, a high-purity sodium channel blocker and 5-HT inhibitor, is widely used in epilepsy and cardiac research for its reproducible action on ion channels. Its physicochemical and mechanistic characteristics enable robust in vitro and BBB permeability assays. This article synthesizes benchmark data, mechanistic rationale, and protocol parameters for translational workflows.

• Applied Cardiogreen (Indocyanine Green): Protocols & PDT Bre

  2026-05-05

  Cardiogreen (Indocyanine Green) bridges gold-standard diagnostics with next-generation photodynamic therapy, enabling high-sensitivity vascular and cellular workflows. Recent breakthroughs show how precise protocol design unlocks robust apoptosis induction and synergistic immuno-oncology effects.

• Sodium Orthovanadate in Signal Transduction: Workflow & Trou

  2026-05-04

  Sodium Orthovanadate (Na3VO4) is the gold-standard reversible inhibitor for preserving phosphorylation states in protein tyrosine kinase assays and metabolic studies. This article details applied workflows, experimental optimizations, and troubleshooting strategies—bridging foundational biochemistry with translational research needs.

• Spatially Patterned Kidney Assembloids: A Leap in Disease Mo

  2026-05-04

  Huang et al. have developed spatially patterned human kidney progenitor assembloids (hKPA) that faithfully recapitulate nephron self-assembly and connect to a central collecting duct, overcoming key limitations of previous organoid systems. This innovation enables high-fidelity in vivo modeling of kidney diseases and offers a robust platform for regenerative nephrology research.

• Tetracycline in Mechanistic Hepatic Fibrosis Models: A Front

  2026-05-03

  Explore how tetracycline, a broad-spectrum polyketide antibiotic, enables advanced modeling of hepatic fibrosis and endoplasmic reticulum stress. This article uniquely bridges ribosomal function research with precision liver disease assays, offering insights not found in existing literature.

• Aclacinomycin A: Precision Tool for Apoptosis & DNA Damage A

  2026-05-02

  Aclacinomycin A (Aclarubicin) stands out as a robust dual topoisomerase inhibitor and apoptosis inducer, offering reproducible and quantifiable performance in cytotoxicity and mechanistic studies. This article details applied workflows, troubleshooting strategies, and protocol optimizations, empowering researchers to unlock precision in DNA damage and cell death assays using APExBIO’s validated compound.

• Calnexin’s Role in CFTR Variant Rescue and Modulator Respons

  2026-05-01

  Tedman et al. systematically dissect the calnexin-dependent expression and pharmacological rescue of over 200 clinical CFTR variants. Their deep mutational scanning approach reveals that calnexin is a critical determinant of both CFTR plasma membrane expression and the efficacy of corrector drugs in a variant- and domain-specific manner, with direct implications for targeted cystic fibrosis therapy development.

• Quizartinib (AC220): Redefining FLT3 Targeting for AML Trans

  2026-05-01

  This thought-leadership article demystifies the mechanistic and translational impact of Quizartinib (AC220) in acute myeloid leukemia (AML) research. By integrating cutting-edge mechanistic insights, experimental best practices, and competitive context, we guide translational researchers through the evolving landscape of FLT3 inhibition. Drawing upon APExBIO's best-in-class Quizartinib, we highlight both challenges and new opportunities for robust model systems, resistance mapping, and clinical innovation—providing actionable guidance beyond the boundaries of conventional product literature.

• Oligo (dT) 25 Beads: Technical Guide for Eukaryotic mRNA Iso

  2026-04-30

  Oligo (dT) 25 Beads address the challenge of isolating highly purified eukaryotic mRNA by leveraging superparamagnetic bead technology for efficient polyA tail mRNA capture. They are best suited for workflows requiring intact mRNA for applications such as cDNA synthesis, RT-PCR, and next-generation sequencing. Use is not recommended for prokaryotic RNA or applications where polyadenylated RNA is absent.

• Peripheral Endosome Entrapment Limits LNP Trafficking and Es

  2026-04-30

  This study employs advanced spatiotemporal tracking to reveal that lipid nanoparticles (LNPs) trapped in peripheral endosomes, rather than lysosomes, significantly hinder intracellular trafficking and cytosolic release. The findings suggest that endosomal escape efficiency depends on precise endolysosomal activity and trafficking dynamics, guiding future design of RNA delivery systems.

• PKM2 Inhibitor (Compound 3k): Beyond Oncology—Metabolic Modu

  2026-04-29

  Explore the unique capabilities of PKM2 inhibitor (compound 3k) as a selective pyruvate kinase M2 inhibitor, with new insights into immune cell metabolism and disease modulation. This article reveals advanced applications and practical guidance distinct from standard cancer-focused reviews.

401 records 9/27 page Previous Next First page 上5页 678910 下5页 Last page